
Dzintars Gotham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7352565/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States. Health Policy, 2021, 125, 296-306.	1.4	29
2	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 527-540.	0.7	48
3	Public investments in the development of GeneXpert molecular diagnostic technology. PLoS ONE, 2021, 16, e0256883.	1.1	12
4	Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries. Journal of Virus Eradication, 2020, 6, 100001.	0.3	23
5	Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. Aids, 2020, 34, 2259-2268.	1.0	30
6	Public investments in the clinical development of bedaquiline. PLoS ONE, 2020, 15, e0239118.	1.1	14
7	Global health research and education at medical faculties in Germany. PLoS ONE, 2020, 15, e0231302.	1.1	8
8	Public investments in the clinical development of bedaquiline. , 2020, 15, e0239118.		0
9	Public investments in the clinical development of bedaquiline. , 2020, 15, e0239118.		Ο
10	Public investments in the clinical development of bedaquiline. , 2020, 15, e0239118.		0
11	Public investments in the clinical development of bedaquiline. , 2020, 15, e0239118.		0
12	Quantifying changes in global health inequality: the Gini and Slope Inequality Indices applied to the Global Burden of Disease data, 1990–2017. BMJ Global Health, 2019, 4, e001500.	2.0	14
13	Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List. BMJ Open, 2019, 9, e027780.	0.8	9
14	Estimated costs of production and potential prices for the WHO Essential Medicines List. BMJ Global Health, 2018, 3, e000571.	2.0	55
15	Production costs and potential prices for biosimilars of human insulin and insulin analogues. BMJ Global Health, 2018, 3, e000850.	2.0	42
16	Cell line access to revolutionize the biosimilars market. F1000Research, 2018, 7, 537.	0.8	0
17	Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?. Journal of Virus Eradication, 2018, 4, 72-79.	0.3	44
18	Open letter to the candidates for Director-General of WHO: will you support a patient-centred R&D agreement?. The Lancet Global Health, 2017, 5, e135-e136.	2.9	6

DZINTARS GOTHAM

#	Article	IF	CITATIONS
19	Estimated generic prices for novel treatments for drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw522.	1.3	19
20	Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. BMJ Open, 2017, 7, e011965.	0.8	30
21	Candidates for inclusion in a universal antiretroviral regimen. Current Opinion in HIV and AIDS, 2017, 12, 324-333.	1.5	30
22	Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. Journal of Virus Eradication, 2016, 2, 28-40.	0.3	60
23	Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open, 2016, 6, e009586.	0.8	49
24	Drug prices threaten the NHS. Lancet, The, 2016, 388, 2603-2604.	6.3	0
25	Global health equity in United Kingdom university research: a landscape of current policies and practices. Health Research Policy and Systems, 2016, 14, 76.	1.1	11
26	How the MDGs gave up on measuring access to medicines. The Lancet Global Health, 2016, 4, e296-e297.	2.9	14
27	Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. Journal of Virus Eradication, 2016, 2, 28-31.	0.3	39
28	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. Journal of Virus Eradication, 2015, 1, 103-110.	0.3	28
29	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. Journal of Virus Eradication, 2015, 1, 103-10.	0.3	16